Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments Company ...

Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes,” ...

ISELIN, N.J., June 10, 2025(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medi ...

"In blind mice, this retinal nanoprosthesis restored the brain’s response to light and improved vision-based behaviors at ...

Can AI really replace scientists? Robin, an AI system, identified a potential drug for vision loss, but scientists are ...

Here is some background information about stem cells. Scientists believe that stem cell research can be used to treat medical conditions including Parkinson’s disease, spinal cord injury, stroke, ...

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD ...

Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not ...

Is it bad to eat eggs every day? Despite mixed public opinion, here’s why this registered dietitian firmly believes that […] ...